関連する実験動画
Updated: Jul 19, 2026

14:28
Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
13.1K
マルチドラッグレジスタンスのタンパク質1を,その柔軟なインタードメインリンクナーを,配列選択ペプチド結合ナノ粒子と結合することによって抑制する
Avijit Ghosh1, Mansi Sharma1, Yan Zhao1
1Department of Chemistry, Iowa State University, Ames, Iowa 50011-3111, United States.
Biomacromolecules
|February 17, 2026
まとめ
分子インプリントされたナノ粒子は,多剤耐性タンパク質1 (MRP1) を標的とし,がん薬剤耐性を克服します. この新しいアプローチは,流出ポンプを阻害し,化学療法に耐性のあるがん細胞を感知させ,薬のIC50値を低下させます.
科学分野:
- バイオケミストリー バイオケミストリー
- ナノテクノロジー ナノテクノロジー
- がん研究 がん研究
背景:
- 多剤耐性タンパク質1 (MRP1) のような過剰発現したATP結合カセット (ABC) トランスポーターは,薬物を排出することによって,がんにおける多剤耐性を誘発する.
- 類似したエフフルスポンプの過剰発現は,細菌の抗菌剤耐性につながる.
研究 の 目的:
- 人間の癌細胞におけるMRP1を標的とし,抑制する配列選択性,分子インプリントナノ粒子 (MINP) を開発する.
- 癌治療における薬剤耐性を克服するMINPの可能性を調査する.
主な方法:
- MRP1の柔軟なリンク器の特定のセグメントを結合するように設計されたMINPの製造.
- MRP1機能と薬物感受性に対するMINP結合の効果を評価するための細胞検査.
- MINPとドクソルビシンで治療されたドックス耐性がん細胞のIC50値の決定.
主要な成果:
- MINPは,MRP1リンクナーのセグメントをマスクし,エフフルスポンプの機能を抑制することに成功した.
- 内膜インターフェースの近くにあるMINPの結合により,MRP1の活性が著しく低下した.
- MINPで治療されたドックス耐性がん細胞は,ドクソルビシンに対する感受性の増加を示し,IC50.5で約25%減少しました.
結論:
- MINPは,細胞内タンパク質を抑制する新しい戦略を代表し,特にMRP1.1をターゲットにしています.
- このアプローチは,細胞を化学療法に敏感にすることで,がんにおける多剤耐性を克服することができます.
- MINPは,非構造タンパク質領域における機能的線形モチーフの識別を容易にする.
関連する概念動画
Protein Digestion
Protein digestion begins in the stomach, where the highly acidic environment can easily disrupt protein structure by exposing the peptide bonds of polypeptide chains. After polypeptide chains are broken into individual amino acids by a series of digestive enzymes, the amino acids are transported to the liver via the bloodstream to produce energy.
Protein Absorption
Proteins in the gastrointestinal tract typically come from food, but they can also originate from disintegrated cells or secreted enzymes. In the stomach, the enzyme pepsin breaks down these proteins into polypeptides. The fragments then move into the duodenum as a semi-fluid mass called chyme. Pancreatic proteases, such as trypsin and chymotrypsin, and intestinal brush border enzymes like carboxypeptidases further dismantle the polypeptides into tripeptides, dipeptides, and free amino acids.
Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

